
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAD2 CRISPR/Cas9 KO Plasmid (h) | sc-401027 | 20 µg | $397.00 | |||
MAD2 HDR Plasmid (h) | sc-401027-HDR | 20 µg | $445.00 |
MAD2L1 encodes the human MAD2 protein, a core component of the spindle assembly checkpoint that monitors kinetochore–microtubule attachment and prevents premature anaphase onset. MAD2 participates in formation of the mitotic checkpoint complex and restrains APC/C activity via CDC20 inhibition, coordinating chromosome segregation and mitotic timing. Perturbation of MAD2L1 disrupts genome stability and can drive aneuploidy, linking this pathway to chromosomal instability phenotypes widely studied in cancer biology. MAD2 also serves as a mechanistic entry point for investigating checkpoint signaling, mitotic stress responses, and crosstalk with DNA damage and cell cycle regulatory networks.
MAD2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MAD2L1 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the MAD2L1 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, MAD2 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined MAD2L1 target site.
When co-transfected with MAD2 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the MAD2L1 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.